Procaps Group SA
NASDAQ:PROC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Henry Schein Inc
NASDAQ:HSIC
|
US |
|
Damon Technology Group Co Ltd
SSE:688360
|
CN |
|
Computer Management Co Ltd
TSE:4491
|
JP |
|
Indiabulls Real Estate Ltd
BSE:532832
|
IN |
Procaps Group SA
Accounts Payable
Procaps Group SA
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Procaps Group SA
NASDAQ:PROC
|
Accounts Payable
$93m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Procaps Group SA
Glance View
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
See Also
What is Procaps Group SA's Accounts Payable?
Accounts Payable
93m
USD
Based on the financial report for Dec 31, 2022, Procaps Group SA's Accounts Payable amounts to 93m USD.
What is Procaps Group SA's Accounts Payable growth rate?
Accounts Payable CAGR 1Y
7%
Over the last year, the Accounts Payable growth was 7%.
